



U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Wallace SE, Bean LJH. Resources for Genetics Professionals — Genetic Disorders Associated with Founder Variants Common in the Newfoundland and Labrador Populations. 2020 Apr 30 [Updated 2023 Aug 17]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.

Bookshelf URL: <https://www.ncbi.nlm.nih.gov/books/>



Resources for Genetics Professionals – Genetic Disorders Associated with Founder Variants Common in the Newfoundland and Labrador Populations

Stephanie E Wallace, MD^{1,2} and Lora JH Bean, PhD^{3,4}

Created: April 30, 2020; Revised: August 17, 2023.

A founder variant is a pathogenic variant observed at high frequency in a specific population due to the presence of the variant in a single ancestor or small number of ancestors. The presence of a founder variant can affect the approach to molecular genetic testing. When one or more founder variants account for a large percentage of all pathogenic variants found in a population, testing for the founder variant(s) may be performed first.

The table below includes common founder variants — here defined as **three or fewer variants that account for >50% of the pathogenic variants identified in a single gene in individuals of a specific ancestry** – in individuals of Newfoundlander and/or Labradorian ancestry. Note: Pathogenic variants that are common worldwide due to a DNA sequence hot spot are not considered founder variants and thus are not included.

Author Affiliations: 1 Senior Editor, GeneReviews; Email: editor2@uw.edu. 2 Clinical Professor, Pediatrics, University of Washington, Seattle, Washington; Email: editor2@uw.edu. 3 Molecular Genetics Editor, GeneReviews. 4 Senior Director, Laboratory Quality Assurance, Perkin-Elmer Genomics, Inc, Pittsburgh, Pennsylvania.

Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

Table. Genetic Disorders Associated with Founder Variants Common in the Newfoundland and/or Labrador Population

Gene	Disorder	MOI	DNA Nucleotide Change (Alias 1)	Predicted Protein Change	Proportion of Pathogenic Variants in Gene 2	Carrier Frequency	Ethnicity (Specific Region)	Reference Sequences	References
<i>APC</i>	Familial adenomatous polyposis, attenuated	AD	c.221-1G>A (IVS2-1G>A)	--	~80%	NA	Newfoundland	NM_00038.6	Spirio et al [1999], Woods et al [2010]
<i>BBS1</i>	Bardet-Biedl syndrome	AR	c.1169T>G	p.Met390Arg	~100% ³	1/67	Newfoundland (southwest)	NM_024649.5 NP_078925.3	Fan et al [2004]
<i>CDH1</i>	Hereditary diffuse gastric cancer	AD	c.2398delC	p.Arg800AlafsTer16	Most families	NA	Newfoundland	NM_004360.5 NP_004351.1	Kaurah et al [2007]
<i>CLDN14</i>	Deafness, AR 29 (OMIM 614035)	AR	c.488C>T	p.Alal163Val	~100% ³	1/44	Newfoundland	NM_144492.3 NP_652763.1	Pater et al [2017]
<i>CLN6</i>	Neuronal ceroid lipofuscinosis 6 (OMIM 601780)	AR	c.268_271dupAACG	p.Val191GlufsTer42	~100% ³	Unknown	Newfoundland (southern coast)	NM_017882.3 NP_060352.1	Moore et al [2008]
<i>F13A1</i>	Factor XIII A deficiency (OMIM 613225)	AR	c.691-1G>A (IVS5-1G>A)	--	86%	Unknown	Newfoundland & Labrador	NM_000129.4	Scully et al [2018]
<i>F8</i>	Hemophilia A	XL	c.6104T>C	p.Val2035Ala	74%	Unknown	Newfoundland & Labrador (Twillingate)	NM_000132.4 NP_000123.1	Scully et al [2018]
<i>MEN1</i>	Multiple endocrine neoplasia type 1	AD	c.1378C>T	p.Arg460Ter	~100%	NA	Newfoundland (Burin Peninsula)	NM_130799.2 NP_570711.1	Olufemi et al [1998]
<i>MSH2</i>	Lynch syndrome	AD	Deletion of exon 8 c.942+3A>T (IVS5+3A>T)	--	<30% ~30%-60%	NA	Newfoundland Newfoundland (northeast coast)	NG_007110.2 NM_000251.3	Stuckless et al [2007], Woods et al [2010]
<i>RLBP1</i>	Newfoundland rod cone dystrophy (OMIM 607476)	AR	c.141+2T>C (IVS3+2T>C) c.141G>A ⁴ (IVS3-1G>A)	--	~20% ~80%	Unknown 1/106	Newfoundland	NM_000326.5	Eichers et al [2002]
<i>STAR</i>	Lipoid congenital adrenal hyperplasia (OMIM 201710)	AR	c.562C>T	p.Arg188Cys	~100% ³	Unknown	Newfoundland & Labrador	NM_000349.3 NP_000340.2	Tsai et al [2016]

Table. continued from previous page.

Gene	Disorder	MOI	DNA Nucleotide Change (Alias 1)	Predicted Protein Change	Proportion of Pathogenic Variants in Gene 2	Carrier Frequency	Ethnicity (Specific Region)	Reference Sequences	References
TMEM43	Arrhythmogenic right ventricular cardiomyopathy	AD	c.1073C>T	p.Ser358Leu	~100% ³	NA	Newfoundland	NM_024334.3 NP_077310.1	Merner et al [2008], Milting et al [2015]
			c.509-1G>C (IVS5-1G>C)	--	33%		Newfoundland (southern coast)	NM_000391.4	
TPP1	Neuronal ceroid lipofuscinosis 2 (OMIM 204500)	AR	c.851G>T	p.Gly284Val	42%	Unknown	Newfoundland (east coast)	NM_000391.4	Moore et al [2008]
			c.1424delC	p.Ser475TrpfsTer13	11%		Newfoundland (northern coast)	NP_000382.3	
VAMPI	Spastic ataxia 1 (See Hereditary Ataxia Overview.)	AD	c.340+2T>G (IVS4+2T>G)	--	~100% ³	NA	Newfoundland	NM_014231.5	Bourassa et al [2012]

Included if ≤ 3 pathogenic variants account for $\geq 50\%$ of variants identified in a specific ethnic group

AD = autosomal dominant; AR = autosomal recessive; MOI = mode of inheritance; NA = not applicable

1. Does not conform to standard HGVS nomenclature

2. This percentage does not account for the possibility of rare *de novo* pathogenic variants occurring in this population.

3. To date, additional pathogenic variants in this gene have not been reported in individuals of Newfoundland and/or Labradorian descent.

4. DNA nucleotide change introduces new splice site and does not result in predicted protein change.

References

- Bourassa CV, Meijer IA, Merner ND, Grewal KK, Stefanelli MG, Hodgkinson K, Ives EJ, Pryse-Phillips W, Jog M, Boycott K, Grimes DA, Goobie S, Leckey R, Dion PA, Rouleau GA. VAMP1 mutation causes dominant hereditary spastic ataxia in Newfoundland families. *Am J Hum Genet.* 2012;91:548–52. PubMed PMID: 22958904.
- Eichers ER, Green JS, Stockton DW, Jackman CS, Whelan J, McNamara JA, Johnson GJ, Lupski JR, Katsanis N. Newfoundland rod-cone dystrophy, an early-onset retinal dystrophy, is caused by splice-junction mutations in RLBP1. *Am J Hum Genet.* 2002;70:955–64. PubMed PMID: 11868161.
- Fan Y, Esmail MA, Ansley SJ, Blacque OE, Borojevich K, Ross AJ, Moore SJ, Badano JL, May-Simera H, Compton DS, Green JS, Lewis RA, van Haelst MM, Parfrey PS, Baillie DL, Beales PL, Katsanis N, Davidson WS, Leroux MR. Mutations in a member of the Ras superfamily of small GTP-binding proteins causes Bardet-Biedl syndrome. *Nat Genet.* 2004;36:989–93. PubMed PMID: 15314642.
- Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA.* 2007;297:2360–72. PubMed PMID: 17545690.
- Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, Kupprion C, Ramadanova K, Thierfelder L, McKenna W, Gallagher B, Morris-Larkin L, Bassett AS, Parfrey PS, Young TL. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. *Am J Hum Genet.* 2008;82:809–21. PubMed PMID: 18313022.
- Milting H, Klauke B, Christensen AH, Müsebeck J, Walhorn V, Grannemann S, Münnich T, Šarić T, Rasmussen TB, Jensen HK, Mogensen J, Baecker C, Romaker E, Laser KT, zu Knyphausen E, Kassner A, Gummert J, Judge DP, Connors S, Hodgkinson K, Young TL, van der Zwaag PA, van Tintelen JP, Anselmetti D. The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. *Eur Heart J.* 2015;36:872–81. PubMed PMID: 24598986.
- Moore SJ, Buckley DJ, MacMillan A, Marshall HD, Steele L, Ray PN, Nawaz Z, Baskin B, Frecker M, Carr SM, Ives E, Parfrey PS. The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland. *Clin Genet.* 2008;74:213–22. PubMed PMID: 18684116.
- Olufemi SE, Green JS, Manickam P, Guru SC, Agarwal SK, Kester MB, Dong Q, Burns AL, Spiegel AM, Marx SJ, Collins FS, Chandrasekharappa SC. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. *Hum Mutat.* 1998;11:264–9. PubMed PMID: 9554741.
- Pater JA, Benteau T, Griffin A, Penney C, Stanton SG, Predham S, Kielley B, Squires J, Zhou J, Li Q, Abdelfatah N, O'Rielly DD, Young TL. A common variant in CLDN14 causes precipitous, prelingual sensorineural hearing loss in multiple families due to founder effect. *Hum Genet.* 2017;136:107–18. PubMed PMID: 27838790.
- Scully MF, Stoffman J, Boyd S. The unusual pattern of hereditary bleeding disorders in the province of Newfoundland and Labrador-Canada's most Eastern Province. *Transfus Apher Sci.* 2018;57:713–6. PubMed PMID: 30455155.
- Spirio L, Green J, Robertson J, Robertson M, Otterud B, Sheldon J, Howse E, Green R, Groden J, White R, Leppert M. The identical 5' splice-site acceptor mutation in five attenuated APC families from Newfoundland demonstrates a founder effect. *Hum Genet.* 1999;105:388–98. PubMed PMID: 10598803.

Stuckless S, Parfrey PS, Woods MO, Cox J, Fitzgerald GW, Green JS, Green RC. The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome. *Fam Cancer*. 2007;6:1-12. PubMed PMID: 17039271.

Tsai SL, Green J, Metherell LA, Curtis F, Fernandez B, Healey A, Curtis J. Primary Adrenocortical Insufficiency Case Series: Genetic Etiologies More Common than Expected. *Horm Res Paediatr*. 2016;85:35-42. PubMed PMID: 26650942.

Woods MO, Younghusband HB, Parfrey PS, Gallinger S, McLaughlin J, Dicks E, Stuckless S, Pollett A, Bapat B, Mrkonjic M, de la Chapelle A, Clendenning M, Thibodeau SN, Simms M, Dohey A, Williams P, Robb D, Searle C, Green JS, Green RC. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. *Gut*. 2010;59:1369-77. PubMed PMID: 20682701.

Revision History

- 17 August 2023 (sw) Revision: added *BBS1* and updated reference sequences
- 30 April 2020 (sw) Initial posting

License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: admasst@uw.edu.